1-(m-chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain

Neuropsychopharmacology

Volumn 24, Issue 5, 2001, Pages 492-501

  Baumann, Michael H ^a   Ayestas, Mario A ^a   Dersch, Christina M ^a   Rothman, Richard B ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

5 HT depletion; d fenfluramine; m chlorophenylpiperazine; Neurotoxicity; Serotonin (5 HT) release

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; AMPHETAMINE DERIVATIVE; DEXFENFLURAMINE; DOPAMINE; PIPERAZINE DERIVATIVE; RADIOLIGAND; SEROTONIN; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISSOCIATION; DOPAMINE BLOOD LEVEL; DOPAMINE RELEASE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; IN VIVO STUDY; LIGAND BINDING; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; SEROTONIN UPTAKE;

ANIMALS; BRAIN; CARRIER PROTEINS; CAUDATE NUCLEUS; CEREBRAL CORTEX; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FENFLURAMINE; HYDROXYINDOLEACETIC ACID; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICRODIALYSIS; NERVE TISSUE PROTEINS; NEURONS; NUCLEUS ACCUMBENS; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TRITIUM;

EID: 0035083653     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00221-9     Document Type: Article

References (58)

1. Effects of high dose fenfluramine treatment on monoamine uptake sites in rat brain: Assessment using quantitative autoradiography
2. Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats
3. GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat
4. The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain
5. Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats
6. The appetite suppressant d-fenfluramine induces apoptosis in human serotonergic cells
7. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine
8. 125I]RTI-55 to dopamine and serotonin transporters in rat brain
9. Single- and multiple-dose kinetics of d-fenfluramine in rats given anorectic and toxic doses
10. Free radicals and the pathobiology of brain dopamine systems
11. Serotonin release estimated by transcortical dialysis in freely-moving rats
12. Fenfluramine and norfenfluramine levels in brain microdialysate, brain tissue, and plasma of rats administered doses of d-fenfluramine known to deplete 5-hydroxytryptamine levels in brain
13. Fenfluramine and brain serotonin
14. 5,6-Dihydroxytryptamine, a serotonin neurotoxin, is formed endogenously in rat brain
15. Valvular heart disease associated with fenfluramine-phentermine
16. Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential
17. Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain
18. Disposition and pharmacological effects of m-chlorophenylpiperazine in rats
19. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: Uptake inhibition versus release
20. On the in vivo and in vitro actions of fenfluramine and its derivatives on central monoamine neurons, especially 5-hydroxytryptamine neurons, and their relation to the anorectic activity of fenfluramine
21. The mechanism of action of fenfluramine
22. Reduction of food intake by manipulation of central serotonin
23. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: Sibutramine is a reuptake inhibitor
24. Tryptamine-4,5-dione, a putative endotoxic metabolite of the superoxide-mediated oxidation of serotonin, is a mitochondrial toxin: Possible implications in neurodegenerative brain disorders
25. Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine
26. Behavioral, biochemical, and neurotoxicological actions of the α-ethyl homologue of p-chloroamphetamine
27. 3H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues
28. m-chlorophenylpiperazine as a probe of serotonin function
29. D-, L-, and DL-Fenfluramine cause long-lasting depletions of serotonin in rat brain
30. Carrier-mediated release of neurotransmitters
31. Dexfenfluramine and serotonin neurotoxicity: Further preclinical evidence that clinical caution is indicated
32. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine
33. Dexfenfluramine: A review of its pharmacological properties and therapeutic potential in obesity
34. Non-neurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine
35. Medicinal chemistry and structure-activity relationships
36. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites
37. Serotonin-releasing effects of substituted piperazines in vitro
38. 2C receptors in CHO-K1 cells
39. Identification of a GBR12935 homolog, LR1111, which is over 4000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters
40. Studies of the biogenic amine transporters. IV. Demonstration of a multiplicity of binding sites in rat caudate membranes for the cocaine analog [125I]RTI-55
41. Aminorex, fenfluramine and chlorphentermine are serotonin transporter substrates: Implications for primary pulmonary hypertension
42. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications
43. Mechanisms of biogenic amine transporters
44. Fluoxetine attenuates the d,l-fenfluramine-induced increase in extracellular serotonin as measured by in vivo microdialysis
45. Long-term effects of p-chloroamphetamine and related drugs on the central serotonergic mechanisms
46. 2 receptor antagonists protect against the neurotoxicity of methylenedioxy methamphetamine in rats
47. 2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: Reversal by L-Dopa
48. 1B receptor ligands exist?
49. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters
50. Fenfluramine administered systemically or locally increases extracellular serotonin in the lateral hypothalamus as measured by microdialysis
51. Methamphetamine and methylenendioxy-methamphetamine neurotoxicity: Possible mechanisms of cell destruction
52. p-chloroamphetamine (PCA), 3,4-methylenedioxymethamphetamine (MDMA) and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT in vivo
53. Long-term effects of fenfluramine on central serotonergic mechanisms
54. Long-term administration of m-chlorophenylpiperazine (mCPP) to rats induces changes in serotonin receptor binding, dopamine levels and locomotor activity without altering prolactin and corticosterone secretion
55. 5-HT transporter is an additional site of action for the 5-HT agonists RU24969 and TFMPP
56. Oxidation of serotonin by superoxide radical: Implications to neurodegenerative brain disorders
57. 5-Hydroxy-3-ethylamino-2-oxindole is not formed in rat brain following a neurotoxic dose of methamphetamine: Evidence that methamphetamine does not induce the hydroxy radical-mediated oxidation of serotonin
58. Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: Pharmacokinetic, dose response, regional specificity and time course data